June 5, 2022 10:20 AM EDTUpdated June 6, 03:44 PM
R&D

#AS­CO22: En­her­tu blows chemother­a­py out of the wa­ter, re­defin­ing breast can­cer sub­groups along the way

Lei Lei Wu

News Reporter

Kyle LaHucik

Senior Reporter

CHICA­GO — When Camille Hertz­ka found out the re­sults of a study show­ing breast can­cer drug En­her­tu cut dis­ease pro­gres­sion or death by about half …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times